Acknowledgement
This work was supported by the Creative Media Service in National Cancer Center, Korea.
References
- Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"-screening and overdiagnosis. N Engl J Med. 2014;371:1765-1767. https://doi.org/10.1056/NEJMp1409841
- Yi KH, Lee EK, Kang H-C, Koh Y, Kim SW, Kim IJ, et al. 2016 revised Korean thyroid association management guidelines for patients with thyroid nodules and thyroid cancer. IJT. 2016;9:59-126.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA. 2021;71:7-33.
- Registry KCC. Annual report of cancer statistics in Korea in 2018. Ministry of Health and Welfare; 2020.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71:209-249.
- Hong S, Won Y-J, Lee JJ, Jung K-W, Kong H-J, Im J-S, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021;53:301. https://doi.org/10.4143/crt.2021.291
- Gottlieb JA, Hill CS, Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974;290:193-197. https://doi.org/10.1056/NEJM197401242900404
- Network NCC. Thyroid Carcinoma; 2009.
- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133. https://doi.org/10.1089/thy.2015.0020
- Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa Sylvia L, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690. https://doi.org/10.1016/j.cell.2014.09.050
- National Comprehensive Cancer Network. Thyroid Carcinoma V.1.2021; 2021.
- Yoo S-K, Song YS, Park YJ, Seo J-S. Recent improvements in genomic and transcriptomic understanding of anaplastic and poorly differentiated thyroid cancers. ENM. 2020;35:44-54.
- Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690. https://doi.org/10.1016/j.cell.2014.09.050
- Song YS, Park YJ. Genomic characterization of differentiated thyroid carcinoma. ENM. 2019;34:1-10.
- Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. The Lancet. 2014;384:319-328. https://doi.org/10.1016/S0140-6736(14)60421-9
- Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630. https://doi.org/10.1056/NEJMoa1406470
- Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: Establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98:31-42. https://doi.org/10.1210/jc.2012-2909
- Lee EK, Kim SM, Kim BH, Kim MJ, Lim DJ, Kim MH, et al. Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: A Korean multicenter retrospective study. Thyroid. 2019;29:1811-1819. https://doi.org/10.1089/thy.2019.0022
- Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, et al. Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: A Korean multicenter study. Thyroid. 2018;28:340-348. https://doi.org/10.1089/thy.2017.0356
- Yan Z, Yang M, Lai CL. Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials. Clin Endocrinol (Oxf). 2021;95:478-488. https://doi.org/10.1111/cen.14479
- Brose MS, Schlumbeger M, Jeffers M, Kappeler C, Meinhardt G, Pena CE. Analysis of biomarkers and association with clinical outcomes in patients with differentiated thyroid cancer: Subanalysis of the sorafenib phase 3 DECISION trial. Clin Cancer Res. 2019;25:7370-7380. https://doi.org/10.1158/1078-0432.ccr-18-3439
- Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: A clinician's perspective. Semin Oncol. 2014;41 Suppl 2:S1-S16.
- Drilon A. TRK inhibitors in TRK fusion-positive cancers. Annals of Oncology. 2019;30:viii23-viii30. https://doi.org/10.1093/annonc/mdz282
- Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731-739. https://doi.org/10.1056/NEJMoa1714448
- Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731-747. https://doi.org/10.1038/s41571-018-0113-0
- Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine. 2019;25:1422-1427. https://doi.org/10.1038/s41591-019-0542-z
- Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825-835. https://doi.org/10.1056/NEJMoa2005651
- Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9:491-501. https://doi.org/10.1016/S2213-8587(21)00120-0
- Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7.
- Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncology. 2020;6:1397-1404. https://doi.org/10.1001/jamaoncol.2020.3362
- Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark Jr TJ, et al. 2021 american thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer guidelines task force. Thyroid. 2021;31:337-386. https://doi.org/10.1089/thy.2020.0944
- Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31:1076-1085. https://doi.org/10.1089/thy.2020.0322